Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Vaxart Receives Up To $453M Award From BARDA For Phase 2b Study Of Oral COVID-19 Vaccine

Author: Benzinga Newsdesk | June 13, 2024 04:16pm

Initial $65.7M For Study Start-Up; Remaining $387.2M Pending Further Study Approval; Enrollment Expected Summer 2024, Interim Analysis By Q1 2025

— 10,000-subject Phase 2b study will evaluate Vaxart's next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator

— Vaxart anticipates initiating enrollment as early as summer 2024

Posted In: VXRT

06/28/2024 Malibu Boats, Inc. (MBUU)

07/01/2024 Equinix, Inc. (EQIX)

07/02/2024 Intel Corporation (INTC)

07/05/2024 AXT, Inc. (AXTI)

07/05/2024 Altimmune, Inc. (ALT)

07/09/2024 Li Auto Inc. (LI)

07/12/2024 Inari Medical, Inc. (NARI)

07/12/2024 Sprout Social, Inc. (SPT)

AnaptysBio Inc (ANAB)